Appointment of Mr. Prasad Reddy Battinapatla as Chief Financial Officer of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical's board, meeting on 7 November 2025, approved unaudited financial results for Q2 and H1 FY26 ended 30 September 2025. Revenue for the quarter stood at Rs 1,430.23 lakhs versus Rs 1,400.52 lakhs in the year-ago quarter, a marginal uptick. However, pre-tax loss widened sharply to Rs 643.78 lakhs from Rs 277.33 lakhs a year earlier, indicating continued pressure on profitability. The board also appointed Mr. Prasad Reddy Battinapatla, a Chartered Accountant with around 15 years of finance experience, as the new Chief Financial Officer effective the same date. Additionally, a postal ballot notice was cleared along with the appointment of scrutinizers for the e-voting process.
The CFO change is a routine key managerial personnel update and is unlikely to move the stock on its own. The widening quarterly loss and negative shareholders' equity of Rs 3,667.92 lakhs are negative signals; the postal ballot hints at a possible fundraising or restructuring move that could be dilutive for existing shareholders.